Ercanetide

Ercanetide
Clinical data
Other names	Cyclo(L-glycyl-L-2-allylproline)
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (8aR)-8a-Prop-2-enyl-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione;
CAS Number	847952-38-9;
PubChem CID	11735696;
DrugBank	DB15601;
ChemSpider	9910403;
UNII	2T1HU6069S;
ChEMBL	ChEMBL4802144;
Chemical and physical data
Formula	C10H14N2O2
Molar mass	194.234 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC[C@@]12CCCN1C(=O)CNC2=O;
	InChI InChI=1S/C10H14N2O2/c1-2-4-10-5-3-6-12(10)8(13)7-11-9(10)14/h2H,1,3-7H2,(H,11,14)/t10-/m0/s1; Key:WVKCGUOWPZAROG-JTQLQIEISA-N;

Ercanetide (INNTooltip International Nonproprietary Name;^[1] developmental code name NNZ-2591) is a synthetic analog of cyclic glycine-proline (cGP) and experimental drug developed for Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome,^[2]^[3] and Prader-Willi syndrome.^[4]

References